Table 1.

Relationship between patients’ characteristics and KRAS mutation status in adenomyosis.

Characteristic	KRAS wild-type patient (N = 44)	KRAS-mutated patient (N = 26)
Median age at operation (range), years	42.5 (21–50)	41 (30–58)
Preoperative treatment, no. (%)	25/44 (56.82)	19/26 (73.08)
DNG, no. (%)	2/44 (4.55)	11/26 (42.31)
GnRHa, no. (%)	23/44 (52.27)	9/26 (34.62)
LNG-IUS, no. (%)	2/44 (4.55)	1/26 (3.85)
PR-IHC
Negative, no. (%)	7/44 (15.91)	13/26 (50)
Disease co-occurrence
Endometriosis, no. (%)	26/44 (59.09)	22/26 (84.62)
EN-OV type, no.(%)	12/44 (27.27)	18/26 (69.23)
EN-DI type, no.(%)	9/44 (20.45)	12/26 (46.15)
EN-PE type, no.(%)	14/44 (31.82)	3/26 (11.54)
Leiomyoma, no. (%)	28/44 (63.64)	13/26 (50.00)
Ovarian cancer, no. (%)	0/44 (0.00)	5/26 (19.23)
Endometrial cancer, no. (%)	0/44 (0.00)	1/26 (3.85)
Cervical cancer, no. (%)	1/44 (2.27)	0/26 (0.00)
MRI
Endometrial subtype, no. (%)	5/44 (11.36)	1/26 (3.85)
Subserous subtype, no. (%)	9/44 (20.45)	7/26 (26.92)
Others (diffuse), no. (%)	28/44(63.64)	18/26 (69.23)
Unknown, no. (%)	2/44 (4.55)	0/26 (0.00)
History
Caesarean section, no. (%)	5/44 (11.36)	0/26 (0.00)
Dilatation and curettage, no. (%)	13/44 (29.55)	7/26 (26.92)
Vaginal delivery, no. (%)	5/44 (11.36)	8/26 (30.77)
Abortion or stillborn, no. (%)	17/44 (38.64)	10/26 (38.46)
Premature birth, no. (%)	1/44 (2.27)	2/26 (7.69)
Hysterectomy, no. (%)	16/44 (36.36)	15/26 (57.69)
Gravidity, no. (%)	23/44 (52.27)	14/26 (53.84)
Smoking history, no. (%)	8/44 (18.18)	3/26 (11.54)

DNG dienogest, EN-DI deep infiltrating endometriosis, EN-OV ovarian endometrioma, EN-PE peritoneal endometriosis, GnRHa gonadotrophin-releasing hormone agonist, PR-IHC immunohistochemistry of progesterone receptors shown in Fig. 7, LNG-IUS levonorgestrel-releasing intrauterine systems